Ignite Creation Date:
2025-12-24 @ 9:16 PM
Ignite Modification Date:
2025-12-29 @ 8:41 PM
Study NCT ID:
NCT05763004
Status:
RECRUITING
Last Update Posted:
2024-10-08
First Post:
2023-01-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
Sponsor:
ImmunOs Therapeutics AG
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-15
Start Date Type:
ACTUAL
Primary Completion Date:
2025-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-01-09
First Submit QC Date:
None
Study First Post Date:
2023-03-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-03
Last Update Post Date:
2024-10-08
Last Update Post Date Type:
ACTUAL